Palvella Therapeutics, Inc. · NASDAQ:PVLA
Palvella Therapeutics — Corporate Update (November 2026)
20 slides from Palvella Therapeutics's corporate update, Nov 19, 2026
Slide 1: QTORIN Docetaxel: Developing the First Potential FDA-Approved Therapy for EMPD
First-in-disease therapies for patients with rare skin diseases QTORIN™ Docetaxel: Developing the First Potential FDA-Approved Therapy for Extramammary Paget’s Disease November 19, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements of Palvella Therapeutics, Inc. (“the Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, and in some cas
Slide 3: QTORIN Docetaxel for Extramammary Paget's Disease (EMPD)
QTORIN™ Docetaxel for Extramammary Paget’s Disease (EMPD) Third product candidate developed from the QTORIN™ platform 1 Serious, Rare, No FDA-approved Therapies 2 QTORIN™ Innovation Applied to Clinically Validated Molecule 3 First for EMPD Patients Debilitating, life-threatening genital and perianal
Slide 4: The Patient Perspective
The Patient Perspective Steve Schroeder, Founder of myEMPD
Slide 5: Living with EMPD: The Patient Perspective
Living with EMPD: The Patient Perspective Patient and founder of myEMPD Advocates for EMPD awareness, community, and research Brings the patient voice to disease research and therapeutic development Connects with patients and clinicians around the world Life-threatening cancer affecting both women a
Slide 6: Disease Overview & Scientific Rationale
Disease Overview & Scientific Rationale Dr. Seemal R. Desai
Slide 7: Dr. Seemal R. Desai, Board-Certified Dermatologist
Dr. Seemal R. Desai, Board-Certified Dermatologist Seemal R. Desai, MD, FAAD Immediate past President of the American Academy of Dermatology (AAD), March 2024 - March 2025 Clinical Associate Professor of Dermatology – University of Texas Southwestern Medical Center Specializes in hard-to-treat vitil
Slide 8: EMPD is a Rare Genital and Perianal Cancer with No FDA-Approved Therapy
EMPD is a Rare Genital and Perianal Cancer with No FDA-Approved Therapy 1. Li et al. (2025) 2. Borghi et al. (2018) 3. Cavadas et al. (2022). Today Primary treatment is surgery Opportunity QTORIN™ docetaxel could transform the treatment paradigm to first-line topical therapy Scrotal EMPD1 Vulvar EMP
Slide 9: EMPD Originates in Apocrine-Rich Skin and Progresses to Metastatic Disease
Epidermis Dermis EMPD Originates in Apocrine-Rich Skin and Progresses to Metastatic Disease Paget Cells in Upper Epidermis1 In Situ Invasive Blood vessels <1mm deep Confined to the epidermis 1-4mm deep Risk of metastasis Paget cell: substantial size, abundant cytoplasm, eccentric nucleus 1. Shaco-Le
Slide 10: QTORIN Docetaxel
QTORIN™ Docetaxel Dr. Jeff Martini, Chief Scientific Officer Dr. David Osborne, Chief Innovation Officer
Slide 11: Docetaxel: Human Clinical Evidence in EMPD
Docetaxel: Human Clinical Evidence in EMPD DOCETAXEL MONOTHERAPY (n=93)1 51.6% ORR 24.7% discontinued due to adverse events 1. Miyashita et al. (2026) 2. Docetaxel has not been approved by the FDA for the treatment of EMPD. 52.7% ≥Grade 3 neutropenia A large and growing real-world evidence base, inc
Slide 12: Docetaxel: An Established and Potent Anti-Cancer Agent
Docetaxel: An Established and Potent Anti-Cancer Agent Locks microtubules in place, stopping dividing cells such as Paget cells Dividing cell Normal Locked Taxanes Stabilize Microtubules Normal: microtubules assemble and break down so the cell can divide Locked: docetaxel stabilizes them, so divisio
Slide 13: QTORIN Docetaxel: Innovation Designed to Overcome Significant Formulation Barriers
QTORIN™ Docetaxel: Innovation Designed to Overcome Significant Formulation Barriers By addressing docetaxel’s formulation challenges, QTORIN™ is designed to unlock its clinical and commercial potential in EMPD Hydrophobic Poor Skin Penetration Unstable QTORIN™ PLATFORM Skin-Targeted Stable Tunable D
Slide 14: Milestones Achieved
Milestones Achieved Selective penetration to the epidermis Favorable preliminary drug stability Payload fine-tuned to optimize tolerability Low systemic absorption anticipated IP: Filed formulation and method-of-use Using QTORIN™, we considered and tested multiple taxanes Molecule Potency Optimal Sk
Slide 15: QTORIN Selectively Targets Disease in Epidermis
Docetaxel 808 Da QTORIN™ Selectively Targets Disease in Epidermis Paget cell (dividing) Keratinocytes Docetaxel QTORIN™ In vitro skin penetration data per Palvella. Note: Docetaxel has not been approved by the FDA for the treatment of EMPD. 1 2 3 1 Break the 500 Da barrier Limit 500 Da 2 Concentrate
Slide 16: QTORIN Docetaxel Clinical Development Plan
QTORIN™ Docetaxel Clinical Development Plan FDA meeting planned 1H 2027 QTORIN™ Docetaxel: From Concept to Clinic Leveraging 505(b)(2) pathway Following pre-IND meeting, Palvella plans to advance to a Phase 2 study IND-enabling study activities initiated
Slide 17: QTORIN Docetaxel EMPD Aligns with Palvella's Pipeline Strategy
QTORIN™ Rapamycin / Pitavastatin Rare Serious Strong Scientific & Biologic Rationale Commercially Attractive No FDA-approved Therapies Highly debilitating and life-threatening cancer >10k U.S. patients2 Docetaxel stabilizes microtubules, preventing cell division and inducing apoptosis None mLMs, cVM
Slide 18: Key Takeaways
Key Takeaways Wes Kaupinen Founder & Chief Executive Officer
Slide 19: Slide 19
Slide 20: Thank You
Striving to be first for rare disease patients Thank You
Palvella Therapeutics — Corporate Update (November 2026) on 6ix